- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (See WARNINGS).
- Combunox™ is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (See WARNINGS).
CombunoxTM (Oxycodone HCl and Ibuprofen) Tablets
Combunox is supplied in a fixed combination tablet form for oral administration and combines the opioid analgesic agent, oxycodone HCl, with the nonsteroidal anti-inflammatory (NSAID) agent, ibuprofen.
Combunox tablet is indicated for the short term (no more than 7 days) management of acute, moderate to severe pain.
Media Articles Related to Combunox (Oxycodone / Ibuprofen)
American Academy of Pain Management Gets a New Name
Source: Medscape Anesthesiology Headlines [2016.09.22]
The American Academy of Pain Management has now become the Academy of Integrative Pain Management, to better reflect the direction pain medicine is taking.
Medscape Medical News
Sleep is key to curing chronic pain
Source: Pain / Anesthetics News From Medical News Today [2016.09.22]
I won't be able to cope with my pain if I don't sleep well' - research from the University of Warwick reveals that the way chronic pain patients think about pain and sleep leads to insomnia and...
Cara Therapeutics to Present Novel Kappa Opioid Receptor Agonist Research at Upcoming Pain Summit
Source: Conferences News From Medical News Today [2016.09.21]
Cara Therapeutics has recently resumed clinical trials for its novel kappa opioid receptor agonist CR845 in managing acute and chronic pain.
NeuroBreak: Politics of Pain; Pot for Autism
Source: MedPage Today Neurology [2016.09.20]
(MedPage Today) -- News and commentary from the world of neurology and neuroscience
Even at Cancer Centers, Finding Relief for Pain Can Be Tough
Source: MedicineNet Cancer Specialty [2016.09.20]
Title: Even at Cancer Centers, Finding Relief for Pain Can Be Tough
Category: Health News
Created: 9/20/2016 12:00:00 AM
Last Editorial Review: 9/20/2016 12:00:00 AM
Published Studies Related to Combunox (Oxycodone / Ibuprofen)
Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study. [2005.01]
BACKGROUND: The sensation of pain arises from both central and peripheral sites, and inflammation may be one of its underlying causes. Combination therapy with analgesic agents having multimodal mechanisms of action and complementary pharmacokinetic properties enhances pain relief by addressing the different pathways of pain while limiting individual drug doses and, therefore, the potential for adverse effects caused by any single agent. Oxycodone and ibuprofen each have been used effectively as monotherapy and in other combinations for the treatment of acute pain; a fixed combination of these analgesics may improve pain relief in the setting of abdominal or pelvic surgery, where trauma and any resultant inflammation may be present at the same time. OBJECTIVE: This study evaluated and compared the analgesic efficacy and tolerability of a single-dose combination tablet containing oxycodone 5 mg/ibuprofen 400 mg with either agent alone and with placebo in women who had undergone abdominal or pelvic surgery... CONCLUSIONS: In this population of women who had undergone abdominal or pelvic surgery, the combination of oxycodone 5 mg/ibuprofen 400 mg was significantly more effective than either agent alone or placebo in the treatment of moderate to severe postoperative pain.
Enfuvirtide: a review of its use in the management of HIV infection. 
Enfuvirtide (Fuzeon), a fusion inhibitor, is indicated in combination with other antiretroviral agents in the treatment of HIV infection in treatment-experienced adults and children aged >6 years.The addition of subcutaneous enfuvirtide to an optimised antiretroviral background regimen improved the virological and immunological response in treatment-experienced HIV-infected patients in the two large, well designed TORO (T-20 vs Optimised Regimen Only) trials...
Page last updated: 2016-09-22